Objectives
This webinar aims to spread awareness of the burden of HIV drug resistance and to advocate to stop HIV drug resistance through implementation of a comprehensive prevention and response approach involving all stakeholders as outlined in the WHO global action plan to prevent, monitor and respond to HIV drug resistance.
The HIV Drug Resistance Report 2021 will be launched at the webinar.
Background
Antiretroviral therapy (ART) has been scaled up at an unprecedented rate: at the end of December 2020, 27.5 million people were receiving ART globally.
As efforts to scale up ART to treat HIV infection and as the use of antiretroviral (ARV) drugs expand to prevent HIV infection (preexposure prophylaxis or PrEP) expand, an increase in the prevalence of drug-resistant HIV is likely.
With the global shift away from the use of non-nucleoside reverse transcriptase inhibitors to the use of the integrase inhibitor dolutegravir, there is a golden opportunity to focus on optimizing the quality of HIV care services to prevent, to the maximum extent possible, emergence of resistance to new ARV drugs. WHO recommends that ART and PrEP programmes be accompanied by measures to monitor the quality of ART and PrEP delivery and by routine surveillance of population-level HIV drug resistance.
The HIV Drug Resistance Report 2021 summarizes the progress in the implementation and the outcomes of the WHO-recommended surveillance and monitoring activities. This webinar is organized as part of the World Antimicrobial Awareness Week 2021.
Webinar
Time: 24 November 2021, 13:00-14:30 CET.
Platform: Zoom. Please register in advance for this webinar
Agenda
Moderator | Irene Mukui, Drugs for Neglected Diseases Initiative (DNDI), Nairobi, Kenya |
Opening remarks | Meg Doherty, Director, Department of Global HIV, Hepatitis and STI Programmes, WHO Haileyesus Getahun, Director, Global Coordination and Partnership on AMR, and Director, Tripartite Joint Secretariat on AMR, WHO |
Launch of the WHO HIV drug resistance report 2021 | Michael Jordan, Consultant, Department of Global HIV, Hepatitis and STI Programmes, WHO |
Stop HIV drug resistance: Comprehensive prevention and response approach | Juliana Da Silva, United States Centers for Disease Control and Prevention Pablo Rojo, Complutense University, Madrid, Spain Ana Claudia Naldinho, Médecins Sans Frontières Collins Otieno, African Society for Laboratory Medicine Mandisa Dukashe, HIV Survivors and Partners Network Moses "Supercharger " Nsubuga, The voice of HIV drug resistance awareness in Uganda |
